论文部分内容阅读
目的观察尿激酶治疗不稳定型心绞痛的临床疗效。方法收集毛郢孜煤矿医院62例确诊为冠心病不稳定心绞痛患者,随机分为常规抗心绞痛组30例,尿激酶组32例,抗心绞痛组常规给予硝酸酯类、Ca~(2+)拮抗剂、β-受体阻滞剂、低分子肝素、阿司匹林等药物;尿激酶组在抗心绞痛组治疗的基础上加用小剂量尿激酶静滴,两组均用药10 d,于治疗期间观察并记录临床症状、心电图和血液流变学检测指标变化。结果尿激酶组有效率100%,抗心绞痛组有效率76.7%,两组治疗后心绞痛发作次数、心电图和血液流变学变化差异有显著性(P<0.01)。结论尿激酶能增强血液的纤溶活性,防止血栓形成和促进血栓溶解,减少或避免 AMI 的发生。
Objective To observe the clinical efficacy of urokinase in the treatment of unstable angina pectoris. Methods Sixty-two patients with unstable angina pectoris diagnosed as CHD were collected from Maohezi coal mine hospital. Thirty patients were randomly divided into routine anti-angina group (n = 30) and urokinase group (n = 32). Anti- Low-molecular-weight heparin, aspirin and other drugs. The urokinase group was given intravenous infusion of low-dose urokinase on the basis of the treatment of anti-angina pectoris group. Both groups were treated for 10 days. During the treatment period, Clinical symptoms, electrocardiogram and hemorheological changes were recorded. Results The effective rate of urokinase group was 100% and that of anti - angina group was 76.7%. There was significant difference between the two groups in the number of angina pectoris, electrocardiogram and hemorheology (P <0.01). Conclusion Urokinase can enhance blood fibrinolytic activity, prevent thrombosis and promote thrombolysis, reduce or avoid the occurrence of AMI.